Man Group’s MaxCyte MXCT Stock Holding History

Man Group’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,836	Closed	-$60.3K	–	2220
2023 Q4	$60.3K	Buy	+12,836	New	+$50K	﹤0.01%	2006
2022 Q2	–	Hold	0	–	–	–	1848

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's MXCT Position: Q1 2024 in Review

Man Group sold out of MaxCyte (MXCT) in Q1 2024, closing a stake of 12,836 shares — an estimated $60.3K sold.

Man Group first reported a position in MXCT in Q4 2023 and held it in 1 quarter. The position peaked at $60.3K in Q4 2023. 123 funds tracked by Wall St. Rank hold MXCT as of Q1 2024.

Man Group reported no remaining MaxCyte position as of Q1 2024 after selling out during the quarter.
Man Group sold 12,836 MaxCyte shares in Q1 2024, an estimated $60.3K.
Man Group first reported a position in MaxCyte in Q4 2023 and held it in 1 quarter.
Man Group's MaxCyte position peaked at $60.3K in Q4 2023.
123 funds tracked by Wall St. Rank held MaxCyte as of Q1 2024.

Based on Man Group's 13F filing for Q1 2024, filed 15 May 2024.